Discovery and origins
Thymosin alpha-1 began as one activity among many in thymosin fraction 5, a partially purified calf-thymus extract that…
From a crude thymus extract to a synthetic immune drug
Thymosin alpha-1 began as one activity among many in thymosin fraction 5, a partially purified calf-thymus extract that restored immune function in animals stripped of their thymus. Isolating and sequencing the single peptide responsible took years of careful work.
This unit traces that arc: the thymus-extract era, the 1977 sequencing of Tα1, the later realization that it is a fragment of prothymosin alpha, and the shift to a chemically synthesized drug that avoids animal-tissue variability.
Key terms
The thymus-extract era
In the 1960s and 1970s, researchers knew the thymus was essential for immune function but not why. Allan Goldstein and colleagues prepared thymosin fraction 5, a crude thymus extract that restored immune responses in animals whose thymus had been removed. It clearly contained something active, but that something was a mixture, not a molecule.
The fraction-5 work mattered because it proved the thymus exported diffusible immune signals, not just a place for cells to mature. That reframing set off a hunt to purify the individual peptides responsible, a hunt that eventually separated the alpha and beta thymosins as distinct molecules.
AdvancedWhy a crude extract was a dead end as a drug
Animal-tissue extracts vary batch to batch in composition and potency and carry contamination and immunogenicity risks. Fraction 5 was a research tool, not a viable pharmaceutical. The path to a usable drug required identifying the single active peptide, determining its exact sequence, and manufacturing it synthetically, which is precisely the arc that produced thymalfasin.